CN1358722A - Process for preparing citrat - Google Patents

Process for preparing citrat Download PDF

Info

Publication number
CN1358722A
CN1358722A CN 01124175 CN01124175A CN1358722A CN 1358722 A CN1358722 A CN 1358722A CN 01124175 CN01124175 CN 01124175 CN 01124175 A CN01124175 A CN 01124175A CN 1358722 A CN1358722 A CN 1358722A
Authority
CN
China
Prior art keywords
compound
structural formula
reaction
formula
cyclization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 01124175
Other languages
Chinese (zh)
Other versions
CN1139590C (en
Inventor
庞宝华
王宁
王晓岩
席尚忠
傅和亮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHANGZHOU TIANPU BIOCHEMICAL PHARMACEUTICAL FACTORY
Original Assignee
CHANGZHOU TIANPU BIOCHEMICAL PHARMACEUTICAL FACTORY
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CHANGZHOU TIANPU BIOCHEMICAL PHARMACEUTICAL FACTORY filed Critical CHANGZHOU TIANPU BIOCHEMICAL PHARMACEUTICAL FACTORY
Priority to CNB011241756A priority Critical patent/CN1139590C/en
Publication of CN1358722A publication Critical patent/CN1358722A/en
Application granted granted Critical
Publication of CN1139590C publication Critical patent/CN1139590C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention discloses a method for preparing compound with structural formula (I) (see patent specification), i.e. preparing sildenafil. Said compound sildenafil is made up another compound with structural formula (II) (see patent specification) through cyclization reaction in the presence of specific alkali. Said method also includes the intermediate product before the compound with structural formula (II) and its preparation process including chlorosulfonation reaction and sulfamidatino reaction with N-methylpiperazine.

Description

The method for preparing Virga
The present invention relates to the preparation method of medicinal heterocyclic compound.Specifically, be exactly that application structure formula (II) compound prepares the method for structural formula (I) compound at specified conditions again by structural formula (III) compound generating structure formula (II) compound.
The molecular structural formula of related compound is,
Figure A0112417500041
Figure A0112417500051
The name of structural formula (I) compound is called 1-[4-oxyethyl group-3-(6,7-dihydro-1-methyl-7-oxidation-3-propyl group-1H-pyrazolo [4,3-d] pyrimidine-5-yl) phenyl sulfonyl]-the 4-methylpiperazine, or claim Virga (Sildenafil).Virga as medicinal compound see Chinese patent " preparation method of Pyrazolopyrimidinoneantianginal antianginal agents " (patent No. ZL 91104162.1), Chinese patent application " prepares the method for liking vigorous ketone " (patent publication No. CN1168376A), and Chinese patent application " method for preparing Virga " (patent publication No. CN 1246478A).Virga citrate treatment male erectile dysfunction has good effect.
Than the above-mentioned background technology, the present invention use easier adopt, the more honest and cleaner raw material of price, use and the substantially different processing method of known technology the preparation Virga.The present invention prepares the method good reaction selectivity of Virga, and yield is very high, and has good practicability.
The processing step of its most critical has three:
(1) structural formula (IV) compound gets reaction product structural formula (III) compound through chlorosulfonation;
(2) structural formula (III) compound and N methyl piperazine sulfuryl amine get reaction product structural formula (II) compound;
(3) structural formula (II) compound obtains structural formula (I) compound, i.e. Virga through cyclization under the condition that specific alkali exists.With usual method Virga and Citric Acid are reacted afterwards, generate the citrate of Virga, can be clinical medicinal.
Used reactant and the reaction conditions of above-mentioned three steps be,
Step (1) is under the condition that chlorsulfonic acid exists, structural formula (IV) compound generation chlorosulfonation, generating structure formula (III) compound.The temperature of chlorosulfonation is controlled at-5~30 ℃, finishes through 8~20 hours.
Step (2) structural formula (III) compound and N methyl piperazine generation amidate action, 0~50 ℃ of controlled temperature was finished through 2~12 hours, made structural formula (II) compound.
The required specific alkali of step (3) cyclization is selected from the basic cpd of alkali family, alkaline-earth metal and phenols, thiophenol class, thio-alcohol formation, for example ArONa (phenol sodium), ArSNa (thiophenol sodium), RSNa (sodium mercaptides), ArOK (phenol potassium), ArSK (thiophenol potassium), RSK (mercaptan potassium) are (in the molecular formula, Ar is an aromatic hydrocarbyl, R is an aliphatic alkyl) etc. one or more and usefulness, wherein the consumption of alkali is 1.0~10.0 moles.
The solvent that cyclization is suitable for is selected from acetonitrile, methyl alcohol, ethanol, propyl alcohol, propyl carbinol, the trimethyl carbinol, 2-butanone, tetrahydrofuran (THF), 1,4-dioxane, dimethyl formamide, pyridine and water and their mixture.
At cyclization post neutralization reaction mixture.Reaction process was carried out 2~72 hours under 50~170 ℃ of temperature condition.
The reaction product of above-described chlorosulfonation, N methyl piperazine amidate action and the cyclization under the alkali existence condition can use that routine techniques separates, purifying.The selectivity that a whole set of technical process shows reaction is good, and yield can reach more than 95%.
Structural formula (I), (II), (III) compound are proved conclusively its structure by ultimate analysis, mass spectroscopy.Structural formula (III) compound passes through again 1H nucleus magnetic resonance (NMR) is further proved conclusively its structure.
In the ultimate analysis, C, H, N content are used Foss CHN-O-Rapid elemental analyser and are measured; The S assay carries out according to People's Republic of China's GB GB4497-84 method.
Mass spectrum FTMS-2000 mass spectrograph record, m/z represents mass-to-charge ratio, M +The expression molecular ion peak, the numeral relative abundance (%) in the bracket.
1H nucleus magnetic resonance (NMR) wave spectrum is with Bruker RM-500 spectrometer record, characterization displacement study (d) be from trimethyl silane to low move 1,000,000/, and with routine representation feature peak: the s that abridges, unimodal; D, doublet; T, triplet; Q, quartet; H, sextet; M, multiplet; Br, broad peak.
Prepare structural formula (I) compound as mentioned above then by the cyclisation and getting under specific alkali existence condition of structural formula (II) compound, structural formula (II) compound is then by structural formula (III) compound and N methyl piperazine generation sulfuryl amine.And required intermediate precursor substance one structural formula (IV) compound of preparation structural formula (III) compound can make by the described route of following reaction scheme.
The reaction scheme of preparation structural formula (IV) compound
Figure A0112417500071
The reaction scheme of preparation structural formula (IV) compound that last figure is indicated, its technical process is as follows:
Structure formula V compound name is called " 3-propyl group pyrazoles-5-ethyl formate ", can make by the method that " Chem.Pharm.Bull., 32:1568,1984 " are put down in writing.
Structure formula V compound through methylate structural formula (VI) compound;
Structural formula (VI) compound gets structural formula (VII) compound through hydrolysis;
Structural formula (VII) compound gets structural formula (VIII) compound through nitration;
Structural formula (VIII) compound gets structural formula (IX) compound through amidation (I);
Structural formula (IX) compound through reduce structural formula (X) compound;
Structural formula (X) compound makes structural formula (IV) compound through amidation once more (II).Structural formula (IV) compound name is called, [4-(2-2 oxygen base phenyl formamide base)-1-methyl-3-propyl group pyrazoles-5-methane amide].
In these reactions, technology of the present invention has been done the following adjustment and improvement than traditional processing method.
1. increased the use of acetone in amidation (I), made more convenient operation, gained intermediate quality is higher, and yield also increases.
2. on the reductive link, abandon tin protochloride (SnCl 2) reduction method, and the shortening method of employing alumino nickel.The benefit of this method has been to reduce the pollution of tin mud to environment, and it is convenient to operate.
3. in amidation (II), do not re-use special additive 4-Dimethylamino pyridine.
4. from the process of structural formula (X) compound structural formula (IV) compound, do not re-use the column chromatography for separation technology.
Make whole technological process be convenient to operation more through above adjustment and improvement, total recovery also increases.
The invention will be further described by the following examples.
Embodiment 1-7 be about structural formula (II) compound in the presence of specific alkali, the example of generating structure formula (I) compound (being Virga).Embodiment 8 is by chlorosulfonation generating structure formula (III) examples for compounds about structural formula (IV) compound.Embodiment 9 is through N methyl piperazine sulfuryl amine generating structure formula (II) examples for compounds about structural formula (III) compound.Embodiment 10 is about preparation structural formula (IV) examples for compounds.
Embodiment 1 preparation structural formula (I) compound
In the four-hole bottle that agitator, reflux condensing tube, thermometer are housed, add structural formula (II) compound 49.20g (0.1mol), add the sodium phenylate 70g (0.6mol) that has prepared again, acetonitrile 250ml stirs.Reflux 5-6 hour.Reaction finishes.Boil off acetonitrile, it is an amount of to add water, uses CH again 2Cl 2Extract, merge CH 2Cl 2Layer with the washing of 5% sodium hydroxide, steams CH 2Cl 2Oven dry gets class in vain so because of body 45.3g, fusing point: 186-188 ℃ yield 95.5%.95% ethyl alcohol recrystallization gets 41.5g, fusing point 188-190 ℃.
Ultimate analysis: measured value C, 55.62%; H, 6.31%; N, 17.7%; S, 6.71%
Theoretical value: C, 55.68%; H, 6.37%; N, 17.71%; S, 6.76%
1HNMR spectrum: δ (CD 3SOCD 3): 0.96 (3H.t), 1.30 (3H, t), 1.77 (2H, h), 2.68 (2H.t), 2.83 (4H, br, S), 2.92 (4H, br, S), 4.18 (3H, S), 4.29 (2H, q), 7.31 (1H, d), 7.80 (2H, m), 12.16 (1H, br, S)
Mass spectrum: m/z:474 (M +, 3.09), 404 (38.44), 312 (100.00), 99 (89.3)
Embodiment 2~7 preparation structural formula (I) compounds
Use and embodiment 1 similar methods, select for use the listed condition of following table to prepare structural formula (I) compound.
Embodiment Alkali Solvent Reaction conditions Reaction times (hour) Yield (%)
????2 Sodium phenylate 1, the 4-dioxane Reflux ????6 ????83.2
????3 Sodium phenylate Ethanol Reflux ????6 ????96.1
????4 Sodium phenylate Acetonitrile Reflux ????8 ????90.6
????5 Methylthio phenol sodium Tetrahydrofuran (THF) Reflux ????12 ????72.1
????6 Butyl sulfhydryl sodium Acetonitrile Reflux ????8 ????65.3
????7 Butyl sulfhydryl sodium 2-butanone Reflux ????8 ????68.7
Embodiment 8 preparation structural formula (III) compounds
Agitator, drying tube are being housed, in the four-hole boiling flask of thermometer, are adding chlorsulfonic acid 120ml and stir, temperature control adds structural formula (IV) compound 33g (0.1mol) below 5 ℃ in batches, after adding, stirs about 5 ℃ of temperature controls, coreaction 12 hours.Reaction is poured reactant in the ice cube into after finishing, and stirs, and uses CH then 2Cl 2500ml scoops up, CH 2Cl 2Layer is used anhydrous sodium sulfate drying, steams CH at last 2Cl 2, oven dry.Get structural formula (III) compound 4.08g, 160 ℃-162 ℃ of fusing points, yield 95.2%.
Ultimate analysis: measured value C, 47.72%; H, 4.89%; N, 13.15%; S, 7.56%
Theoretical value: C, 47.61%; H, 4.94%; N, 13.07%; S, 7.48%
Mass spectrum: m/z:428.9 (M +, 4.01), 358.9 (35.32), 330.0 (100.00), 166 (25.41)
Embodiment 9 preparation structural formula (II) compounds
Add structural formula (III) compound 40.8g in the four-hole boiling flask that agitator, drying tube, thermometer are housed, dehydrated alcohol 300ml stirs.Add N methyl piperazine 24g then in batches, stirred under the room temperature 6 hours, after reaction finishes, filter, washing, dry 44.8g, yield 95.6%, 206 ℃-208 ℃ of fusing points.Get 41.2% behind 95% ethyl alcohol recrystallization, 208 ℃-210 ℃ of fusing points.
Ultimate analysis: measured value C, 53.72%; H, 6.52%; N, 17.13%; S, 6.47%
Theoretical value: C, 53.65%; H, 6.55%; N, 17.06%; S, 6.51%
Mass spectrum: m/z:492 (M +, 3.86), 422 (30.52), 329 (80.41), 99 (100.00)
Embodiment 10 preparation structural formula (IV) compounds
Preparation structural formula (IV) compound carries out according to the following steps:
1, preparation structural formula (VI) compound---1-methyl-3-propyl group pyrazoles-5-ethyl formate
In the round-bottomed flask of reflux condensing tube is housed, adding structure formula V compound---3-propyl group pyrazoles-5-ethyl formate 31.9g (0.18mol) (presses Chem.Pharm.Bull., 32:1568,1984 method makes) and methyl-sulfate 22.1g (0.18mol), controlled temperature reacted 2.5 hours in 90 ℃, be cooled to room temperature, add methylene dichloride 50ml, get light brown liquid 29.1g, yield 82.4%.
2. prepare structural formula (VII) compound---1-methyl-3-propyl group pyrazoles-5-formic acid
In agitator, reflux condensing tube there-necked flask are housed, add structural formula (VI) compound---1-methyl-3-propyl group pyrazoles-5-ethyl formate 19.6g (0.1mol), 6mol.L -1Sodium hydroxide 50ml, reflux 3 hours is after the ice-water bath cooling, with the 6mol.L of precooling -1Hydrochloric acid is transferred pH to 2, obtains white solid 14.3g after the filtration, 150~154 ℃ of fusing points, yield 85.2%.
3. prepare structural formula (VIII) compound---1-methyl-4-nitro-3-propyl group pyrazoles-5-formic acid
In agitator, reflux condensing tube there-necked flask are housed, add oleum 18ml, nitrosonitric acid 15ml adds structural formula (VII) compound more in batches---and 1-methyl-3-propyl group pyrazoles-5-formic acid 16.8g (0.1mol) keeps temperature to be lower than 60 ℃.After adding, 60 ℃ of heated overnight after the cooling, are poured on ice, obtain white solid 19.4g after the filtration, 124~127 ℃ of fusing points, yield 91.2%.
4. prepare structural formula (IX) compound---1-methyl-4-nitro-3-propyl group pyrazoles-5-methane amide
Agitator is being housed, in the there-necked flask of reflux condensing tube, is adding structural formula (VIII) compound---1-methyl-3-propyl group pyrazoles-5-formic acid 21.3g (0.1mol), thionyl chloride 50ml, reflux 3 hours, after the cooling, the remaining thionyl chloride of pressure reducing and steaming, cooling, add 50ml acetone, then the acetone solution thing is poured into carefully in the mixture of ice 50g and strong aqua 50ml, obtain faint yellow solid 17.8g after the filtration, 141~143 ℃ of fusing points, yield 84.1%.
5. prepare structural formula (X) compound---4-amino-1-methyl-3-propyl group pyrazoles-5-methane amide
In the autoclave of 1 liter, add structural formula (IX) compound---1-methyl-4-nitro-3-propyl group pyrazoles-5-methane amide 21.3g (0.1mol), alumino nickel 20g, 95% ethanol 300ml, hydrogenation is caught up with oxygen post-heating to 70 ℃, slowly feed hydrogen, press in treating to reach 50kg/cm 2Shi Jixu leads to hydrogen, then reduces to normal pressure and filters, and solution goes in the 500ml there-necked flask, steams ethanol, gets gray solid, gets white crystal 14.9g, 98~101 ℃ of fusing points, yield 81.9% behind recrystallization.
6. prepare structural formula (IV) compound---4-(2-ethoxyl phenenyl formamido group)-1-methyl-3-propyl group pyrazoles-5-methane amide
In the there-necked flask that agitator, reflux condensing tube and dropping funnel are housed, add structural formula (X) compound---4-amino-1-methyl-3-propyl group pyrazoles-5-ammonium formate 18.2g (0.1mol), triethylamine 20g (0.2mol), methylene dichloride 300ml, cryosel is bathed and is cooled to below 0 ℃, stir, drip the mixture of 2-ethylphenyl formyl chloride 36.1g (0.2mol) and methylene dichloride 300ml.Finish, stirred 2 hours under the room temperature, add methyl alcohol 15ml, use 2mol.L -1Organic layer is told in hydrochloric acid 200ml washing, and anhydrous sodium sulfate drying boils off solvent, and solid gets white solid 31.2g with amount of ethyl acetate-hexane (1: 2) washing, is structural formula (IV) compound, 153~155 ℃ of fusing points, yield 94.6%.

Claims (8)

1. the method for preparing structural formula (I) compound, it is characterized in that, comprise reaction conditions by the cyclization of structural formula (II) compound generating structure formula (I) compound, structural formula (IV) compound prepares structural formula (III) compound through chlorosulfonation, carries out the reaction conditions that sulfonamide reaction prepares structural formula (II) compound by structural formula (III) compound and N methyl piperazine again.
Figure A0112417500021
Figure A0112417500031
2. according to the method for claim 1, it is characterized in that, is to carry out under the condition that has specific alkali to exist by the cyclization of structural formula (II) compound generating structure formula (I) compound.
3. according to the method for claim 1, it is characterized in that, under 50~170 ℃ of temperature condition, carry out by the cyclization of structural formula (II) compound generating structure formula (I) compound.
4. according to the method for claim 1, it is characterized in that, by cyclization flow process time of structural formula (II) compound generating structure formula (I) compound be 2~72 hours.
5. according to the method for claim 2, it is characterized in that, used alkali is selected from the basic cpd of alkali family, alkaline-earth metal and phenols, thiophenol class, thio-alcohol formation, comprise that ArONa (phenol sodium), ArSNa (thiophenol sodium), RSNa (sodium mercaptides), ArOK (phenol potassium), ArSK (thiophenol potassium), RSK (mercaptan potassium) are (in the molecular formula, Ar is an aromatic hydrocarbyl, and R is an aliphatic alkyl) one or more and use.
6. according to the method for claim 1, it is characterized in that, cyclization solvent for use by structural formula (II) compound generating structure formula (I) compound is selected from acetonitrile, methyl alcohol, ethanol, propyl alcohol, propyl carbinol, the trimethyl carbinol, 2-butanone, tetrahydrofuran (THF), 1,4-dioxane, dimethyl formamide, pyridine and water and their mixture.
7. according to the method for claim 1, it is characterized in that structural formula (IV) compound carries out chlorosulfonation and prepares structural formula (III) compound under the condition that chlorsulfonic acid exists, its temperature of reaction is at-5~30 ℃, and the reaction times is 8~20 hours.
8. according to the method for claim 1, it is characterized in that structural formula (III) compound and N methyl piperazine carry out sulfonamide reaction, preparation structural formula (II) compound, its temperature of reaction is 0~50 ℃, the reaction times is 2~12 hours.
CNB011241756A 2001-08-21 2001-08-21 Process for preparing citrat Expired - Lifetime CN1139590C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB011241756A CN1139590C (en) 2001-08-21 2001-08-21 Process for preparing citrat

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB011241756A CN1139590C (en) 2001-08-21 2001-08-21 Process for preparing citrat

Publications (2)

Publication Number Publication Date
CN1358722A true CN1358722A (en) 2002-07-17
CN1139590C CN1139590C (en) 2004-02-25

Family

ID=4665560

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB011241756A Expired - Lifetime CN1139590C (en) 2001-08-21 2001-08-21 Process for preparing citrat

Country Status (1)

Country Link
CN (1) CN1139590C (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012097750A1 (en) 2011-01-21 2012-07-26 浙江大德药业集团有限公司 Pyrazolopyrimidinone compound and imidazo-triazone compound for treating erectile dysfunction
CN102690273A (en) * 2012-06-07 2012-09-26 杭州奥默医药技术有限公司 Preparation method of sildenafil
CN103044331A (en) * 2013-01-14 2013-04-17 常州市亚邦医药研究所有限公司 Novel method for preparing Sildenafil intermediate 4-amino-1-methyl-3-n-propyl-pyrazole-5-formamide
CN106117212A (en) * 2016-06-25 2016-11-16 吉林医药学院 A kind of sldenafil synthesis technique of improvement
CN109970744A (en) * 2019-04-10 2019-07-05 重庆康刻尔制药有限公司 A kind of synthetic method of sildenafil citrate intermediate

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012097750A1 (en) 2011-01-21 2012-07-26 浙江大德药业集团有限公司 Pyrazolopyrimidinone compound and imidazo-triazone compound for treating erectile dysfunction
CN102690273A (en) * 2012-06-07 2012-09-26 杭州奥默医药技术有限公司 Preparation method of sildenafil
CN103044331A (en) * 2013-01-14 2013-04-17 常州市亚邦医药研究所有限公司 Novel method for preparing Sildenafil intermediate 4-amino-1-methyl-3-n-propyl-pyrazole-5-formamide
CN103044331B (en) * 2013-01-14 2017-09-15 常州市亚邦医药研究所有限公司 Prepare the new method of the formamide of 3 n-propyl pyrazoles of silaenafil intermediate 4 amino, 1 methyl 5
CN106117212A (en) * 2016-06-25 2016-11-16 吉林医药学院 A kind of sldenafil synthesis technique of improvement
CN106117212B (en) * 2016-06-25 2019-10-11 吉林医药学院 A kind of improved silaenafil synthesis technology
CN109970744A (en) * 2019-04-10 2019-07-05 重庆康刻尔制药有限公司 A kind of synthetic method of sildenafil citrate intermediate

Also Published As

Publication number Publication date
CN1139590C (en) 2004-02-25

Similar Documents

Publication Publication Date Title
CN1229366C (en) Methanesulphonamido-benzofuran derivative, preparation method and use thereof as synthesis ntermediate
CN1300118C (en) Preparation method of 4-(3-chlor-4-fluorobenzeneamidocyanogen)-7-methoxy-6-(3-morpholine oxypropyl)quinazoline
US10689349B2 (en) Method for producing intermediate of biotin and method for producing biotin
CN1155568C (en) Method for producing 3-alkanoylindoles and 3-alkylindoles
CN1681796A (en) Process for the preparation of 4- (3'-chloro-4'-fluoroanilino) -7-methoxy-6- (3-morpholinopropoxy) quinazoline
CN101062897A (en) Improved process for preparing 2,3-dihydro-1H-indenes-1-amine and derivative thereof
CN1139590C (en) Process for preparing citrat
CN100338069C (en) Process for the preparation of olanzapine and an intermediate therefor
CN101514168A (en) Synthesis of 2-hydroxy-n,n-dimethyl-3-[[2-[1(r)-(5-methyl-2-furanyl) propyl]amino]-3,4-dioxo-1-cyclobuten-1-yl]amino]benzamide
JPH01221374A (en) Production of 4-oxo-1-benzopyran-2-carboxylic acid derivative having optical activity, intermediate for synthesizing said derivative and production of said intermediate
CN1092660C (en) Process for preparing Xidinafei
CN1738808A (en) Cyclization process for substituted benzothiazole derivatives
CN1310884C (en) Method for producing enantiomer-free N-methyl-N-[(1S)-1-phenyl-2-[(3S)-3-hydroxypyrrolidine-1-y1)ethyl]-2, 2-diphenyl acetamide
CN113336703B (en) Synthesis of 1,3,4, 5-tetrasubstituted 1H-pyrazole derivatives
CN112778317B (en) Synthetic method of [1,2,4] triazolo [1,5-a ] pyrimidine compound
JP6963435B2 (en) Method for producing intermediate of biotin and method for producing biotin
JP2014510698A (en) Atobacon manufacturing method
CN1603324A (en) Leavo halogenated salt and its preparation process and use
CN112778189A (en) (3R,4S) -N-substituent-3-carboxylic acid-4-ethyl pyrrolidine, intermediate and lapatinib
CN1422265A (en) Method for producing benzo annelated heterocycles
CN1235880C (en) Quinolinenone kind derivative and its accetable salt, its preparation method, application in preparation of alipyrazole and preparation of alipyrazole
CN1151137C (en) Method of producing thiobarbituric acid derivatives
CN1506347A (en) Fluoridized benzaldehyde
CN112430205B (en) Preparation method of arylpyrrole compound
CN1206713A (en) Process for preparing 2-chloro-benzimidazole derivatives

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: CHANGZHOU TIANPU PHARMACY CO., LTD.

Free format text: FORMER NAME OR ADDRESS: CHANGZHOU TIANPU BIOCHEMICAL PHARMACEUTICAL FACTORY

CP03 Change of name, title or address

Address after: Wujin hi tech Industrial Development Zone, Jiangsu, Changzhou

Patentee after: Changzhou universal Pharmaceutical Co., Ltd.

Address before: No. 1, Changhong West Road, Changzhou, Jiangsu, Hutang

Patentee before: Changzhou Tianpu Biochemical Pharmaceutical Factory

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20040225